
TY  - JOUR
TI  - Abstracts
JO  - HPB
VL  - 8
IS  - s2
SN  - 1365-182X
UR  - https://doi.org/10.1080/16515320600855338
DO  - doi:10.1080/16515320600855338
SP  - 3
EP  - 256
PY  - 2006
ER  - 

TY  - JOUR
TI  - Abstracts 544 - 1089
JO  - American Journal of Transplantation
VL  - 4
IS  - s8
SN  - 1600-6135
UR  - https://doi.org/10.1111/j.1600-6135.2004.0480b.x
DO  - doi:10.1111/j.1600-6135.2004.0480b.x
SP  - 308
EP  - 456
PY  - 2004
ER  - 

TY  - JOUR
TI  - Oral Abstracts
JO  - American Journal of Transplantation
VL  - 18
IS  - S4
SN  - 1600-6135
UR  - https://doi.org/10.1111/ajt.14917
DO  - doi:10.1111/ajt.14917
SP  - 245
EP  - 478
PY  - 2018
ER  - 

TY  - JOUR
TI  - Abstracts - Thurday 26th July 2001
JO  - Scandinavian Journal of Immunology
VL  - 54
IS  - s1
SN  - 0300-9475
UR  - https://doi.org/10.1046/j.1365-3083.2001.0540s1004.x
DO  - doi:10.1046/j.1365-3083.2001.0540s1004.x
SP  - 4
EP  - 4
PY  - 2001
ER  - 

TY  - JOUR
TI  - Orals
JO  - Transplant International
JA  - Transpl Int
VL  - 26
IS  - s2
SN  - 0934-0874
UR  - https://doi.org/10.1111/tri.12210
DO  - doi:10.1111/tri.12210
SP  - 1
EP  - 184
PY  - 2013
ER  - 

TY  - JOUR
TI  - Abstracts Oral Presentations – Educational Day
JO  - Clinical & Experimental Immunology
VL  - 154
IS  - s1
SN  - 0009-9104
UR  - https://doi.org/10.1111/j.1365-2249.2008.03767.x
DO  - doi:10.1111/j.1365-2249.2008.03767.x
SP  - 1
EP  - 224
PY  - 2008
ER  - 

TY  - JOUR
TI  - 39th meeting of Scandinavian Society for Immunology jointly with the Baltic Immunological Society June 2-5, 2010, Tallinn, Estonia
JO  - Scandinavian Journal of Immunology
VL  - 71
IS  - 6
SN  - 0300-9475
UR  - https://doi.org/10.1111/j.1365-3083.2010.02398.x
DO  - doi:10.1111/j.1365-3083.2010.02398.x
SP  - 474
EP  - 548
PY  - 2010
ER  - 

TY  - JOUR
TI  - Posters (Abstracts 264–2239)
JO  - Hepatology
JA  - Hepatology
VL  - 66
IS  - S1
SN  - 0270-9139
UR  - https://doi.org/10.1002/hep.29501
DO  - doi:10.1002/hep.29501
SP  - 149
EP  - 1185
PY  - 2017
ER  - 

TY  - JOUR
TI  - 5th Joint Meeting of the European Tissue Repair Society and the Wound Healing Society
JO  - Wound Repair and Regeneration
VL  - 17
IS  - 4
SN  - 1067-1927
UR  - https://doi.org/10.1111/j.1524-475X.2009.00519.x
DO  - doi:10.1111/j.1524-475X.2009.00519.x
SP  - A54
EP  - A87
PY  - 2009
ER  - 

TY  - JOUR
TI  - Abstracts 1–204
JO  - Hepatology
JA  - Hepatology
VL  - 50
IS  - S4
SN  - 0270-9139
UR  - https://doi.org/10.1002/hep.23300
DO  - doi:10.1002/hep.23300
SP  - 302A
EP  - 401A
PY  - 2009
ER  - 

TY  - JOUR
TI  - Plenary Paper
JO  - Journal of the American Geriatrics Society
JA  - J Am Geriatr Soc
VL  - 61
IS  - s1
SN  - 0002-8614
UR  - https://doi.org/10.1111/jgs.12263
DO  - doi:10.1111/jgs.12263
SP  - S1
EP  - S232
PY  - 2013
ER  - 

TY  - JOUR
TI  - Abstracts of the IPITA-IXA-CTS 2015 Joint Congress November 15–19, 2015, Melbourne, Australia
JO  - Xenotransplantation
JA  - Xenotransplantation
VL  - 22
IS  - S1
SN  - 0908-665X
UR  - https://doi.org/10.1111/xen.12205
DO  - doi:10.1111/xen.12205
SP  - S48
EP  - S120
PY  - 2015
ER  - 

TY  - JOUR
TI  - Abstracts—Poster
JO  - Alcoholism: Clinical and Experimental Research
VL  - 34
IS  - s2
SN  - 0145-6008
UR  - https://doi.org/10.1111/j.1530-0277.2010.01210.x
DO  - doi:10.1111/j.1530-0277.2010.01210.x
SP  - 11A
EP  - 243A
PY  - 2010
ER  - 

TY  - JOUR
TI  - Oral Presentation Abstracts
JO  - International Journal of Rheumatic Diseases
JA  - Int J Rheum Dis
VL  - 20
IS  - S1
SN  - 1756-1841
UR  - https://doi.org/10.1111/1756-185X.13177
DO  - doi:10.1111/1756-185X.13177
SP  - 3
EP  - 16
PY  - 2017
ER  - 

TY  - JOUR
TI  - Posters
JO  - Glia
JA  - Glia
VL  - 61
IS  - S1
SN  - 0894-1491
UR  - https://doi.org/10.1002/glia.22530
DO  - doi:10.1002/glia.22530
SP  - S49
EP  - S216
PY  - 2013
ER  - 

TY  - JOUR
TI  - 125th annual meeting: American Neurological Association
JO  - Annals of Neurology
JA  - Ann Neurol.
VL  - 48
IS  - 3
SN  - 0364-5134
UR  - https://doi.org/10.1002/ana.410480301
DO  - doi:10.1002/ana.410480301
SP  - 407
EP  - 552
PY  - 2000
ER  - 

TY  - JOUR
TI  - Poster Abstract
JO  - European Journal of Clinical Investigation
JA  - Eur J Clin Invest
VL  - 47
IS  - S1
SN  - 0014-2972
UR  - https://doi.org/10.1111/eci.12749
DO  - doi:10.1111/eci.12749
SP  - 87
EP  - 178
PY  - 2017
ER  - 

TY  - JOUR
AU  - Loera-Valencia, R.
AU  - Cedazo-Minguez, A.
AU  - Kenigsberg, P.A.
AU  - Page, G.
AU  - Duarte, A.I.
AU  - Giusti, P.
AU  - Zusso, M.
AU  - Robert, P.
AU  - Frisoni, G. B.
AU  - Cattaneo, A.
AU  - Zille, M.
AU  - Boltze, J.
AU  - Cartier, N.
AU  - Buee, L.
AU  - Johansson, G.
AU  - Winblad, B.
TI  - Current and emerging avenues for Alzheimer's disease drug targets
JO  - Journal of Internal Medicine
JA  - J Intern Med
VL  - 286
IS  - 4
SN  - 0954-6820
UR  - https://doi.org/10.1111/joim.12959
DO  - doi:10.1111/joim.12959
SP  - 398
EP  - 437
KW  - AD gene therapy
KW  - AD molecular targets
KW  - AD therapeutics
KW  - alzheimer´s disease
KW  - amyloid beta therapies
KW  - Tau therapies
PY  - 2019
AB  - Abstract Alzheimer's disease (AD), the most frequent cause of dementia, is escalating as a global epidemic, and so far, there is neither cure nor treatment to alter its progression. The most important feature of the disease is neuronal death and loss of cognitive functions, caused probably from several pathological processes in the brain. The main neuropathological features of AD are widely described as amyloid beta (A?) plaques and neurofibrillary tangles of the aggregated protein tau, which contribute to the disease. Nevertheless, AD brains suffer from a variety of alterations in function, such as energy metabolism, inflammation and synaptic activity. The latest decades have seen an explosion of genes and molecules that can be employed as targets aiming to improve brain physiology, which can result in preventive strategies for AD. Moreover, therapeutics using these targets can help AD brains to sustain function during the development of AD pathology. Here, we review broadly recent information for potential targets that can modify AD through diverse pharmacological and nonpharmacological approaches including gene therapy. We propose that AD could be tackled not only using combination therapies including A? and tau, but also considering insulin and cholesterol metabolism, vascular function, synaptic plasticity, epigenetics, neurovascular junction and blood?brain barrier targets that have been studied recently. We also make a case for the role of gut microbiota in AD. Our hope is to promote the continuing research of diverse targets affecting AD and promote diverse targeting as a near-future strategy.
ER  - 

TY  - JOUR
TI  - Scientific Program
JO  - American Journal of Transplantation
VL  - 8
IS  - s2
SN  - 1600-6135
UR  - https://doi.org/10.1111/j.1600-6143.2008.02253.x
DO  - doi:10.1111/j.1600-6143.2008.02253.x
SP  - 57
EP  - 176
PY  - 2008
ER  - 

TY  - JOUR
TI  - 33rd Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF)
JO  - Experimental Dermatology
VL  - 15
IS  - 3
SN  - 0906-6705
UR  - https://doi.org/10.1111/j.1600-0625.2006.00403.x
DO  - doi:10.1111/j.1600-0625.2006.00403.x
SP  - 187
EP  - 257
PY  - 2006
ER  - 
